Age at Diagnosis of Pheochromocytoma Differs According to Catecholamine Phenotype and Tumor Location
Open Access
- 1 February 2011
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 96 (2) , 375-384
Abstract
Context: Pheochromocytomas and paragangliomas (PPGLs) are diagnosed earlier in patients with hereditary than sporadic disease. Whether other factors influence age at diagnosis is unclear. Objective: We examined ages at which PPGLs were diagnosed according to different catecholamine phenotypes and locations of tumors. Design & Setting: Retrospective multicenter study. Patients: Patients with PPGLs included 172 with and 183 without identified germline mutations or hereditary syndromes. Biochemical Measurements: Differences in plasma concentrations of metanephrine, a metabolite of epinephrine, were used to distinguish epinephrine-producing tumors from those lacking epinephrine production. Results: Patients with epinephrine-producing tumors were diagnosed 11 yr later (P < 0.001) than those with tumors lacking appreciable epinephrine production. Among patients without evidence of a hereditary condition, those with and without epinephrine-producing tumors had respective mean ± se ages of 50 ± 2 and 42 ± 2 yr (P < 0.001) at diagnosis. Patients with multiple endocrine neoplasia type 2 and neurofibromatosis type 1, all with epinephrine-producing tumors, were similarly diagnosed with disease at a later age than patients with tumors that lacked appreciable epinephrine production secondary to mutations of von Hippel-Lindau and succinate dehydrogenase genes (40 ± 2 vs. 31 ± 1 yr, P < 0.001). Among the latter patients, those with multifocal tumors were diagnosed earlier than those with solitary tumors (19 ± 3 vs. 34 ± 2 yr, P < 0.001). Conclusions: The variations in ages at diagnosis associated with different tumor catecholamine phenotypes and locations suggest origins of PPGLs from different chromaffin progenitor cells with variable susceptibility to disease causing mutations. Different optimal age cut-offs for mutation testing are indicated for patients with and without epinephrine-producing tumors (44–49 vs. 30–35 yr, respectively).Keywords
This publication has 28 references indexed in Scilit:
- SDHA is a tumor suppressor gene causing paragangliomaHuman Molecular Genetics, 2010
- Germline mutations in TMEM127 confer susceptibility to pheochromocytomaNature Genetics, 2010
- Clinical Predictors and Algorithm for the Genetic Diagnosis of Pheochromocytoma PatientsClinical Cancer Research, 2009
- The kinesin KIF1Bβ acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressorGenes & Development, 2008
- Genetic Testing in PheochromocytomaAnnals of the New York Academy of Sciences, 2006
- Pheochromocytoma Catecholamine Phenotypes and Prediction of Tumor Size and Location by Use of Plasma Free MetanephrinesClinical Chemistry, 2005
- Clinical Characteristics of Pheochromocytoma Patients With Germline Mutations in SDHDJournal of Clinical Oncology, 2005
- Differences between sporadic and multiple endocrine neoplasia type 2A phaeochromocytomaClinical Endocrinology, 1998
- Phaeochromocytoma in multiple endocrine neoplasia type 2 A: survey of 100 casesClinical Endocrinology, 1993
- Mutation and Cancer: Statistical Study of RetinoblastomaProceedings of the National Academy of Sciences, 1971